Renaissance Technologies (RenTech)'s CATX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 59,133 shares of Perspective Therapeutics, Inc. (CATX) worth $201,644, representing 0.00% of the portfolio. First purchased in 2024-Q2, this short-term holding has been held for 7 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in CATX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 352,493 shares. Largest reduction occurred in Q1 2026, reducing 352,493 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Perspective Therapeutics (CATX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Perspective Therapeutics (CATX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +59,133 | New Buy | 59,133 | $3.41 |
| Q1 2026 | -352,493 | Sold Out | 0 | $0.00 |
| Q4 2025 | +352,493 | New Buy | 352,493 | $2.75 |
| Q2 2025 | -163,460 | Sold Out | 0 | $0.00 |
| Q1 2025 | +163,460 | New Buy | 163,460 | $2.13 |
| Q3 2024 | -61,660 | Sold Out | 0 | $0.00 |
| Q2 2024 | +61,660 | New Buy | 61,660 | $9.97 |
Renaissance Technologies (RenTech)'s Perspective Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Perspective Therapeutics, Inc. (CATX) in Q2 2024, acquiring 61,660 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Perspective Therapeutics, Inc. (CATX) for 7 quarters since Q2 2024.
Renaissance Technologies (RenTech)'s largest addition to Perspective Therapeutics, Inc. (CATX) was in Q4 2025, adding 352,493 shares worth $969,356.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 59,133 shares of Perspective Therapeutics, Inc. (CATX), valued at approximately $201,644.
As of the Q2 2026 filing, Perspective Therapeutics, Inc. (CATX) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Perspective Therapeutics, Inc. (CATX) was 352,493 shares, as reported at the end of Q4 2025.